Most Recent
Biotech company Cryosite has agreed to a $1 million settlement for losses resulting from legal advice received in relation to a merger agreement that left the company facing $1.05 million in penalties for engaging in cartel conduct.
Two units of US pharmaceutical giant Pfizer have filed a lawsuit seeking damages from Juno Pharmaceuticals for allegedly infringing the patent for post-operative pain drug Dynastat.
A judge has signed off on a $40 million settlement reached in shareholder class action against Sirtex, including a $10 million cut for the funders, saying commission rates should reflect the risks taken by funders.
US biotechnology company Regeneron Pharmaceuticals has filed a Federal Court challenge after losing its opposition to a patent application by UK biopharmaceutical company Kymab for a method of producing an animal with part-human DNA.
A Sydney-based law firm has over 200 lawsuits in the pipeline against medical professionals across the country seeking compensation for injuries caused by allegedly dangerous pelvic mesh implants.
Ariosa Diagnostics has asked the Full Federal Court to hear its challenge to a ruling that its Harmony prenatal test infringed Sequenom's patent for a prenatal genetic test, saying the court's judgment was attended by "sufficient doubt".
Global pharmaceutical firm Pfizer is mulling an application to stay a lawsuit by Merck Sharp & Dohme seeking to invalidate a patent related to the blockbuster Prevnar 13 vaccine as it awaits the outcome of similar proceedings in the US.
AFT Pharmaceuticals has challenged a Federal Court decision that found its Maxisegic ads were misleading and deceptive, saying the judge "set the bar too high" by requiring it to prove there was an adequate scientific foundation for its painkiller representations.
Online healthcare platform HealthEngine is facing legal action by the Australian Competition and Consumer Commission, accused of hiding 17,000 negative reviews, altering thousands of other reviews and selling patient's personal data to insurers.
The plaintiffs in The Cosmetic Institute class action over allegedly botched breast implants will argue a former director of the company was the mastermind behind the ‘one size fits all’ business model, after the business went into liquidation and stopped participating in litigation.